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Abstract
Objective To use the rs1229984 variant in the alcohol dehydrogenase
1B gene (ADH1B) as an instrument to investigate the causal role of
alcohol in cardiovascular disease.
Design Mendelian randomisation meta-analysis of 56 epidemiological
studies.
Participants 261 991 individuals of European descent, including 20 259
coronary heart disease cases and 10 164 stroke events. Data were
available on ADH1B rs1229984 variant, alcohol phenotypes, and
cardiovascular biomarkers.
Main outcome measures Odds ratio for coronary heart disease and
stroke associated with the ADH1B variant in all individuals and by
categories of alcohol consumption.
Results Carriers of the A-allele of ADH1B rs1229984 consumed 17.2%
fewer units of alcohol per week (95% confidence interval 15.6% to
18.9%), had a lower prevalence of binge drinking (odds ratio 0.78 (95%
CI 0.73 to 0.84)), and had higher abstention (odds ratio 1.27 (1.21 to
1.34)) than non-carriers. Rs1229984 A-allele carriers had lower systolic
blood pressure (−0.88 (−1.19 to −0.56) mm Hg), interleukin-6 levels
(−5.2% (−7.8 to −2.4%)), waist circumference (−0.3 (−0.6 to −0.1) cm),
and body mass index (−0.17 (−0.24 to −0.10) kg/m2). Rs1229984 A-allele
carriers had lower odds of coronary heart disease (odds ratio 0.90 (0.84
to 0.96)). The protective association of the ADH1B rs1229984 A-allele
variant remained the same across all categories of alcohol consumption
(P=0.83 for heterogeneity). Although no association of rs1229984 was
identified with the combined subtypes of stroke, carriers of the A-allele
had lower odds of ischaemic stroke (odds ratio 0.83 (0.72 to 0.95)).
Conclusions Individuals with a genetic variant associated with
non-drinking and lower alcohol consumption had a more favourable
cardiovascular profile and a reduced risk of coronary heart disease than
those without the genetic variant. This suggests that reduction of alcohol
consumption, even for light to moderate drinkers, is beneficial for
cardiovascular health.
Introduction
Alcohol is the fifth leading risk factor for death and disability
accounting for 4% of life years lost due to disease.1 While the
harmful effects of alcohol on conditions such as liver cirrhosis,
injuries, and cancers of the liver, colorectum, breast, and upper
aerodigestive tract have been firmly established,2 uncertainty
remains concerning the potential protective effects of light to
moderate alcohol consumption on risk of coronary heart disease
and stroke.3-5 Observational studies have consistently reported
that compared with non-drinkers, light to moderate drinking
exhibits a reduced cardiovascular risk,6 7 with the lowest risk
found at approximately 12-25 British units per week, while
heavier and more hazardous drinking is associated with an
increased risk, resulting in the well established U shaped
association.2 8 However, the apparent cardioprotective effect
associated with light to moderate drinking could be explained
by an elevated cardiovascular risk from underlying poor health
in non-drinkers,9 or confounding by lifestyle or social factors
associated with light to moderate drinking.10
The most widely proposed mechanism for this purported
cardioprotective effect of alcohol is an increase in high density
lipoprotein (HDL) cholesterol.11 However, the causal nature of
the association of HDL cholesterol with cardiovascular events
is unclear.12 13 Although an HDL cholesterol raising effect of
alcohol has been reported in experimental studies,11 the small
sample size and short follow-up means existing studies may be
prone to bias, undermining their validity.
In the absence of a viable randomised trial to confirm or refute
the cardioprotective effect of light to moderate alcohol
consumption, an alternative approach is to use a genetic variant
that serves as a proxy for alcohol consumption. This approach,
known as Mendelian randomisation, avoids some of the key
limitations of observational studies, since allocation of genetic
variants is random with regard to potential confounders, and
genotype is not modified by disease (abolishing reverse
causality).14 15 A non-synonymous single nucleotide
polymorphism (rs1229984) in the alcohol dehydrogenase 1B
gene (ADH1B), which encodes the ADH1B enzyme, which
provides the primary pathway of alcohol metabolism,16 has been
associated with a flush response to alcohol consumption, lower
levels of usual alcohol consumption and blood ethanol levels,17
as well as a lower risk of alcohol dependence among adult
drinkers18 19 and adolescents,19 which led to the selection of this
single nucleotide polymorphism as a genetic instrument in
previousMendelian randomisation studies that investigated the
role of alcohol in high blood pressure and various cancers.20-23
We present results from an international collaboration that used
the ADH1B rs1229984 variant as an instrument to investigate
the association of alcohol with cardiovascular biomarkers and
events in more than 260 000 individuals.
Correspondence to: J P Casas, Faculty of Epidemiology and Public Health, London School of Hygiene & Tropical Medicine, London WC1E 7HT,
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Methods
Formation of the consortium
Given that the rs1229984 genetic variant is not represented in
widely available genotyping platforms such as
Illumina-metabochip, Illumina-immunochip, or genome-wide
association platforms (with the exception of recent platforms),
we initially focused on studies genotyped with the IBC
Cardiochip array, which contains this single nucleotide
polymorphism (SNP). Through contact with the designer of the
Institute for Translational Medicine and Therapeutics (ITMAT)
Broad Institute CARe consortium (IBC) CardioChip array (B
J Keating,24 coauthor), we contacted all population based studies
genotyped on this array. Subsequently, we established contact
with a series of genetic study groups with whom we have
collaborated in the past and sent them a brief proposal describing
the general aims of the study, including de novo genotyping in
their studies. A minor subset of studies in European descent
population that used this variant in previous publications was
also identified and included in the consortium (details available
in table S1 in the appendix on bmj.com). In addition, we checked
publicly available consortia such as CARDIoGRAMplusC4D
(www.cardiogramplusc4d.org) and found the SNP was not
included in these consortia.
We incorporated individual participant data from 261 991
participants of European ancestry from 56 studies (see
appendix). All participants provided written, informed consent,
and ethical approval was granted by local ethics committees for
participating studies. Ethical approval for secondary data
analysis was granted by the London School of Hygiene &
Tropical Medicine ethics committee (application No 5905).
Alcohol traits
The principal alcohol trait was weekly volume of alcohol in
British units (1 British unit is equivalent to 0.57 US units or 10
ml (7.9 g) ethanol), which we derived using questionnaire data
from each study (table S2 in the appendix). We additionally
assessed the overall drinking status (drinkers v non-drinker) of
study subjects, the study specific top tertile of alcohol
consumption (separately for men and women), and history of
binge drinking (for details see supplementary methods 2.1).
γ-glutamyltransferase was used as a marker of heavy alcohol
consumption.
Clinical outcomes
The primary clinical event was incident and prevalent (including
fatal and non-fatal) coronary heart disease. Secondary clinical
outcomes were stroke and type 2 diabetes. Stroke included all
subtypes and consisted of incident and prevalent (including fatal
and non-fatal) cases. In a subsample, information on ischaemic
stroke was also available. For type 2 diabetes, we restricted the
analysis to prevalent cases with the exception of one nested
case-cohort that included incident cases.25 Precise definitions
of outcomes for each study are reported in table S3 of the
appendix.
Genotype properties
Genotyping platforms, genotype frequencies, Hardy Weinberg
equilibrium P values, and call rates (median of 98.8%) for
ADH1B rs1229984 (directly genotyped in all studies) are listed
in table S1 and figure S1 of the appendix.
Statistical analysis
A standard analysis protocol was applied to each study to
produce a consistent dataset. Analyses were conducted using
individual participant data in each study and then pooled across
studies using meta-analysis. Because of differences in variables
collected by each study, not all studies were included in all
analyses (fig S2 of appendix). We restricted analyses to
individuals of European descent with data forADH1B rs1229984
genotype, age, sex, and any one of the outcomes of interest. All
non-normally distributed continuous variables, including
units/week of alcohol, were natural log transformed. For these
traits, the mean difference on the logarithmic scale was
exponentiated to generate the relative difference and then
converted to a percentage difference.
We investigated the shape of the association between alcohol
consumption (log units/week) and cardiovascular biomarkers
and potential confounders in observational analysis among 131
490 individuals from 28 studies. Statistical details are given in
supplementary methods 2.2 of the appendix.
For all genetic analyses, we used a dominant model due to the
low prevalence of the rs1229984 A-allele (average carriage of
rs1229984 A-alleles: 7%): data from carriers of either one or
two rare A-alleles were pooled and compared with individuals
homozygous for the G-allele (the reference group). We first
quantified the effects of rs1229984 A-allele on alcohol traits as
well as on lifestyle and social factors to validate our instrument
for alcohol consumption. Then, we studied the associations of
the rs1229984 A-allele with cardiovascular biomarkers from
several pathways that may mediate the effects of alcohol on
cardiovascular events. Finally, we evaluated the effects of the
rs1229984 A-allele on coronary heart disease, combined
subtypes of stroke (as well as ischaemic stroke separately) and
type 2 diabetes.
For continuous traits, means and standard deviations were
derived for rs1229984 A-allele carriers and non-carriers. For
binary traits, log odds ratios and standard errors were estimated
for rs1229984 A-allele carriers versus non-carriers. All effect
estimates were calculated within each study and then pooled
using fixed (default) and random effects meta-analysis. Between
study heterogeneity was quantified using I2.26
If the U shaped association between alcohol consumption and
cardiovascular events is real, a comparison of event rates in
rs1229984 A-allele carriers (associated with a reduction in
alcohol consumption from published studies20) versus
non-carriers will vary across broad categories of alcohol
consumption. In light to moderate drinkers (>0 to <21
units/week), ADH1B rs1229984 A-allele carriers will be
expected to have a higher coronary heart disease event risk,
whereas, for heavy drinkers (≥21 units/week) they will be
expected to have a lower event risk. Likewise, this stratification
by alcohol consumption will also serve to validate the ADH1B
rs1229984 A-allele variant as a specific instrument for alcohol
consumption, as it is expected that in non-drinkers carriage of
the rs1229984 A-allele variant will have no effect on
cardiovascular traits or events, or a substantially attenuated
effect given the known difficulty in correctly classifying long
term non-drinkers from self reported questionnaires.27Therefore,
we repeated the genetic analysis in strata of alcohol intake (none
(0 units/week), light to moderate (>0 to <21 units/week), and
heavy (≥21 units/week); the strata were selected to represent
the U shaped association of alcohol and cardiovascular events
from observational studies) and investigated if there was a trend
between alcohol categories and the effect of rs1229984 A-allele
using meta-regression (see supplementary methods 2.3 of
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appendix for further details). The same stratified analysis was
conducted for potential confounders, to investigate if
confounding was reintroduced by stratifying by alcohol.28 For
units/week of alcohol consumption (our main alcohol
phenotype), we also performed a subgroup analysis according
to the type of alcohol questionnaire (according to whether
consumption questions asked separately for beverage type (such
as beer, wine, spirits) v all beverages combined). Exploratory
subgroup analyses were undertaken to assess the impact of study
characteristics included sex, mean age, geographical region,
Hardy Weinberg equilibrium, genotype platform, year of DNA
extraction, and, whether the study contributed to observational
analysis.
In order to investigate potential residual confounding by
population stratification, we adjusted for principal components
derived from IBC CardioChip array24 in studies with available
data (see supplementary methods 2.4 for further details). To
evaluate confounding by linkage disequilibrium between
rs1229984 with single nucleotide polymorphisms associated
with cardiovascular risk factors in genome-wide association
studies29 that could distort associations of rs1229984, we used
theWhitehall-II cohort30 (including both IBC CardioChip24 and
MetaboChip31 platforms).
In the current manuscript, we did not conduct an instrumental
variable analysis to estimate causal effects since the available
methods assume a linear association between the exposure and
the outcome, which may not hold for alcohol and cardiovascular
disease.
Analyses were conducted in Stata v13.0 (StataCorp, Texas,
USA). All P values reported are two sided.
Results
We approached 59 studies, of which 56 were included in this
collaboration. Of the three excluded studies, two
(INTERHEART and INTERSTROKE) declined to participate
because of overlap with existing projects, and a third (CoLaus)
was excluded as the rs1229984 genetic variant was not directly
genotyped.
Of the 261 991 participants in our analysis, 48% were women,
and the mean age per study was 58 years (range 26-75 years)
(table S4 of appendix). The median number of alcohol units
consumed in each study is shown in table S4. There were 20
259 coronary heart disease events, 10 164 stroke cases (4339
ischaemic strokes) and 14 549 type 2 diabetes cases (table S5).
Means and distributions for continuous traits in all studies are
presented in tables S6-S8. The observational analysis between
alcohol and cardiovascular risk factors is reported in the
supplementary results section and figures S2 and S3 of the
appendix.
Genetic association analysis
ADH1B and alcohol consumption
Carriers of the rs1229984 A-allele consumed fewer units of
alcohol per week (−17.2% units/week (95% confidence interval
−18.9% to −15.6%)) and had lower odds of being in the top
third of drinking volume (odds ratio 0.70 (0.68 to 0.73))
compared with non-carriers. Rs1229984 A-allele carriers also
had lower odds of binge drinking (odds ratio 0.78 (0.73 to 0.84)),
increased odds of being self reported abstainers (odds ratio 1.27
(1.21 to 1.34)) and lower levels of γ-glutamyltransferase (−1.8%
(−3.4% to −0.3%)) (table 1⇓).
The association of the rs1229984 A-allele with alcohol volume
remained unaltered when stratified by age, gender, geographical
region, Hardy Weinberg Equilibrium P value, and whether the
alcohol questionnaire used was beverage specific (fig S4 of
appendix), or after exclusion of samples with a proportion of
A-allele carriers >10% (approximately >5% minor allele
frequency; data available on request). Ameta-regression analysis
of the mean alcohol volume (on the log scale) in rs1229984
A-allele carriers compared with non-carriers that takes into
account the uncertainty around the mean suggested a constant
proportional effect of the of ADH1B rs1229984 variant on
alcohol volume (fig S5). This was also supported by the finding
that in our samples the standard deviations for carriers and
non-carriers were very similar (fig S6).
ADH1B and cardiovascular biomarkers
Carriers of the rs1229984 A-allele had lower systolic blood
pressure (−0.88 (−1.19 to −0.56) mm Hg) compared with
non-carriers. Concordant with this, rs1229984 A-allele carriers
also had lower odds of hypertension (104 570 cases; odds ratio
0.94 (0.91 to 0.98)). Rs1229984 A-allele carriers had lower
levels of interleukin-6 (−5.2% (−7.8% to −2.4%)), C reactive
protein (−3.4% (−5.7% to −1.1%)), body mass index (−0.17
(−0.24 to −0.10) kg/m2), and waist circumference (−0.34 (−0.58
to −0.10) cm). Rs1229984 A-allele carriers also had lower
non-HDL cholesterol concentrations (−0.03 (−0.05 to −0.01)
mmol/L) (table 2⇓).
When the effect of the ADH1B rs1229984 A-allele on these
cardiovascular traits was stratified by alcohol consumption, a
differential effect was observed. Among heavy drinkers (≥21
units/week), carriers of the rs1229984 A-allele, who on average
consume 17.2% less alcohol than non-carriers, showed a more
pronounced reduction in these cardiovascular traits than that
observed in light to moderate drinkers and non-drinkers (fig
1⇓). In contrast, the effect of rs1229984 on these cardiovascular
traits did not differ systematically according to exploratory
subgroup analyses by laboratory procedures or study
characteristics (P>0.05 for 52 of 58 comparisons; fig S7 of
appendix).
Although we observed that rs1229984 A-allele carriers had
higher triglyceride levels (1.6% (0.7% to 2.6%)), this effect was
not modified by alcohol categories (fig 1⇓).
There was no overall difference between rs1229984 A-allele
carriers and non-carriers in HDL cholesterol concentration
(−0.004 (−0.012 to 0.003) mmol/L). However, an association
between rs1229984 A-allele carriage with HDL cholesterol was
observed in the highest category of alcohol consumption, but
in the opposite direction to that expected from observational
findings (0.04 (0.02 to 0.06) mmol/L; fig S8 of appendix). (That
is, the log-linear association of HDL cholesterol with alcohol
consumption from observational studies (fig S3) would suggest
that a reduction in alcohol consumption, as observed for carriers
of the rs1229984 A-allele, should associate with a reduction in
HDL cholesterol levels.) In subgroup analysis by laboratory
procedures and major study characteristics, we observed that
rs1229984 A-allele carriers from northern Europe had lower
levels of HDL cholesterol (−0.04 (−0.05 to −0.02) mmol/L).
Since this geographical specificity could reflect residual
population stratification in samples outside northern Europe,
we adjusted for principal components in a subset of individuals
not from northern Europe. The unadjusted model for the
association between rs1229984 A-allele and HDL cholesterol
(0.02 difference in standard deviation (95% confidence interval
−0.02 to 0.06)) did not differ from the model adjusted for
population structure (0.01 difference in standard deviation
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(−0.03 to 0.05)) (fig S8). Similar null results were observed for
apolipoprotein A1 (table S9 of appendix).
Rs1229984 A-allele carriage was not associated with carotid
intima medial thickness, electrocardiographic measures of left
ventricular hypertrophy, fibrinogen, von Willebrand factor,
factor VII, fasting blood glucose, N-terminal of the prohormone
brain natriuretic peptide, or lipoprotein(a) overall (table S9 of
appendix). For these traits, similar null results were observed
when stratified for alcohol consumption or by other exploratory
subgroups (P>0.05 for 47 of 48 comparisons, data available on
request), with the exception of fasting glucose and lipoprotein(a),
where the strength of association wasmore pronounced in heavy
drinkers compared with other alcohol categories (P values for
heterogeneity 0.05 and 0.01, respectively) (fig S9).
ADH1B and lifestyle factors
Carriage of the rs1229984 A-allele was not associated with
physical activity, but showed higher odds of ever smoking (odds
ratio 1.06 (95% confidence interval 1.02 to 1.09)). However,
the association with ever smoking was in the opposite direction
to that seen in observational analysis, and no association was
observed for other quantitative measures of tobacco exposure
such as cigarettes per day, pack years, or cotinine levels.
Rs1229984 A-allele carriers showed higher total years in
education (0.04 difference in standard deviation (95%
confidence interval 0.01 to 0.08)). No differential effect of
ADH1B on any of the lifestyle factors was identified on
stratifying by alcohol intake (making it unlikely that stratifying
by alcohol introduced bias) or by other exploratory subgroups
(P>0.05 for all comparisons) (figs S10 and S11 of appendix).
ADH1B and cardiovascular events
Rs1229984 A-allele carriage showed reduced odds of coronary
heart disease (odds ratio 0.90 (95% confidence interval 0.84 to
0.96, I2=17%)) (fig 2⇓ and fig S12 of appendix). In studies with
≥1000 coronary heart disease events (four studies with 8374
coronary heart disease events), the odds ratio for coronary heart
disease was 0.81 (0.72 to 0.91, I2=0%) (table S10). When
analysis was restricted to non-drinkers the association was null
(odds ratio 0.98 (0.88 to 1.10)), while among drinkers (>0
units/week alcohol), carriers of the rs1229984 A-allele had
reduced odds of coronary heart disease (odds ratio 0.86 (0.78
to 0.94)). This is consistent with the assumption that the
associations ascribed to the ADH1B variant are mainly due to
alcohol consumption. Further subdivision of the drinkers
category into light (>0 to <7 units/week), moderate (≥7 to <21
units/week), and heavy (≥21 units/week) showed the same
protective effect of the variant across all alcohol categories (P
value for heterogeneity=0.83; fig 2⇓), suggesting that there was
no difference between rs1229984 A-allele carriers and
non-carriers in coronary heart disease risk across alcohol
consumption levels among individuals who drank.
Although there was no association of the rs1229984 A-allele
with the combined stroke subtypes (odds ratio 0.98 (0.90 to
1.07)) (fig 3⇓), when the analysis was limited to ischaemic
stroke subtype, rs1229984 A-allele carriers had lower odds of
ischaemic stroke (odds ratio 0.83 (0.72 to 0.95)) (fig S13 of
appendix). No association between rs1229984 A-allele with
type2 diabetes was observed (odds ratio 1.02 (0.95 to 1.09))
(fig 3⇓).
Random effect estimates for associations of ADH1B with all
outcomes were similar to those from fixed effect models (figs
S4-14 of appendix).
Adjustment for population structure did not alter the rs1229984
A-allele associations (figs S15-16). The gene variant was not
in linkage disequilibrium with previously reported loci from
genome-wide association studies for any cardiovascular trait
(table S11).
Discussion
Principal findings of study
In this large scaleMendelian randomisation analysis, we showed
that carriers of the rs1229984 A-allele had lower levels of
alcohol consumption and exhibited lower levels of blood
pressure, inflammatory biomarkers, adiposity measures, and
non-HDL cholesterol, and reduced odds of developing coronary
heart disease, compared with non-carriers of this allele. In
contrast to previous observational and experimental studies, our
study showed that individuals with a genetic predisposition to
consume less alcohol had lower, not higher, odds of developing
coronary heart disease regardless of whether they were light,
moderate, or heavy drinkers. Moreover, ADH1B genotype was
not associated with type 2 diabetes, HDL cholesterol level, or
coagulation markers.
The rs1229984 A-allele showed very strong association with
non-drinking and amount of alcohol consumed. The fact that
our analyses suggested a constant proportional effect of the
rs1229984 A-allele on alcohol volume across a wide range of
alcohol volume from the included studies supports the notion
that social pressure in heavier drinking cultures is unlikely to
override the effect of the genetic variant on alcohol
consumption.20 It is important to note that the rs1229984A-allele
was a proxy for all types of self reported drinking behaviour
including volume, being in the top third of drinkers per study,
binge drinking, and abstention, and it also showed association
with levels of the liver enzyme γ-glutamyltransferase (an
objective marker of heavy alcohol intake). This confirms that
rs1229984 was suitable as a non-specific genetic proxy of
alcohol consumption in the mendelian randomisation analysis.
Our findings are therefore not specific to one particular type of
alcohol behaviour, but reflect a combination of different patterns
of alcohol exposures, which are nevertheless directionally
concordant (that is, the A-allele resulted in lower alcohol
consumption).
For the cardiovascular traits that showed association on overall
with the rs1229984 A-allele, null or substantially reduced
associations were observed in non-drinkers and more
pronounced associations in heavy drinkers when compared with
light to moderate drinkers. This is as expected under the
assumption that the effect of this genetic variant is only
explained by exposure to alcohol.
From the U shaped association seen in observational studies,
we would expect that for drinkers below the nadir (12-25
units/week), a reduction of 17.2% in alcohol consumption
(corresponding to rs1229984 A-allele carriage) would lead to
a small increase in the risk of coronary heart disease, whereas
for those with alcohol consumption above the nadir, a similar
reduction in alcohol consumption would lead to a decrease in
coronary heart disease risk. Contrary to these expectations,
however, we found that individuals below the nadir with a
genetic predisposition to consume less alcohol had lower odds
of developing coronary heart disease at all categories of alcohol
consumption (fig 2⇓), bringing the hypothesised cardioprotective
effect of alcohol into question.
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Strengths and weaknesses of the study
Major strengths of this international collaboration are the large
sample size, availability of detailed alcohol phenotypic data and
a comprehensive repertoire of cardiovascular risk factors and
major cardiovascular events. The process by which studies were
recruited into the collaboration, including mainly unpublished
data, means that findings are unlikely to suffer from publication
bias. The use of a standardised analytical protocol further
increases reliability of the findings.
The lack of association of the ADH1B rs1229984 A-allele with
HDL cholesterol levels was unexpected. In principle, failure to
detect an association with HDL cholesterol could have arisen
from lack of power. However, this is unlikely as rs1229984 was
associated with traits (such as C reactive protein or interleukin
6) for which alcohol consumption had a less powerful effect
and where the sample size for genetic analysis was several times
smaller than for HDL cholesterol (fig S2 of appendix). Our
extensive subgroup and in silico analyses also suggested it was
unlikely that laboratory technique, type of alcohol questionnaire
used in the studies, or confounding by linkage disequilibrium
could explain the overall null effect. We did find an association
of rs1229984 A-allele carriage with HDL cholesterol in the
subset of northern European studies. Although this suggests the
lack of association in non-northern European studies may arise
from population stratification, adjustment for population
structure using principal components analysis did not reveal an
association, making this an unlikely explanation.
We also did not identify associations of the rs1229984 A-allele
with coagulation markers, type 2 diabetes, and the combined
subtypes of stroke. With regard to coagulation markers, these
results seem more robust for fibrinogen, as confirmed by
subgroup analysis. For factor VII and von Willebrand factor,
reduced sample size limited our ability to exclude a small effect.
Although we observed an overall null association of the
rs1229984 A-allele with type 2 diabetes and blood glucose
concentration, a stratified analysis by alcohol consumption
showed that, among heavy drinkers, carriers of the rs1229984
A-allele had lower levels of glucose and a directionally
consistent relationship with type 2 diabetes. It is interesting that
we did not observe a stronger protective association of coronary
heart disease in heavy drinkers for carriers of the ADH1B
variant, as we observed for cardiovascular risk factors. This is
likely to reflect reduced power due to the low number of
coronary heart disease events in the heavy drinking stratum.
The relatively small number of stroke events is an important
limitation, as well as the use of combined stroke subtypes, which
could have obscured some differential associations of alcohol
by pathological or aetiological subtype, as suggested by recent
overviews from observational studies.7 In this context it is
interesting to note than in a subset of studies, we found the
rs1229984 A-allele associated with reduced odds of ischaemic
stroke, but this requires replication.
One of the advantages of a mendelian randomisation study is
that this design is less prone to some of the biases of
observational studies. In contrast to observational analyses that
have shown associations of alcohol with physical activity and
different measures of smoking,32 rs1229984 A-allele was not
associated with physical activity or any of the more precise
measures of smoking exposure (cigarettes/day, pack years, or
cotinine level). However, an association was observed with the
binary ever/never smoking trait, but this was in the opposite
direction to the association with coronary heart disease and is
therefore unlikely to explain the association of rs1229984
A-allele with a reduced risk of coronary heart disease. There
was also some evidence for a difference in years of education,
and, while the size of the effect was small, this requires further
investigation.
Strengths andweaknesses in relation to other
studies
Our findings compare with findings from studies in east Asians,
using the rs671 genetic variant of the aldehyde dehydrogenase
2 gene (ALDH2), that have also shown associations of alcohol
with blood pressure, bodymass index, and non-HDL cholesterol
levels.21 22However, the association with coronary heart disease
events remains unclear since the association of ALDH2 with
coronary heart disease has been analysed only in small
studies.21 22 In contrast to our findings, ALDH2 rs671 has shown
an association with HDL cholesterol levels in individuals of
Asian ancestry.21 In Europeans the ALDH2 rs671 variant is
monomorphic and cannot be used for mendelian randomisation,
and previous studies have therefore used the ADH1B genotype
to investigate the effect of alcohol on cardiovascular disease.20-34
Our results not only replicate findings of ADH1B on blood
pressure and body mass index from smaller data collections,
but expand the number of cardiovascular traits and includemajor
vascular events. Given our large sample size, we are able to
identify associations with other cardiovascular traits (non-HDL
cholesterol, interleukin 6, and C reactive protein), and most
notably we are able to detect for the first time an association
with coronary heart disease.
One feature in common to both ALDH2 and AHD1B for
mendelian randomisation is the use of genetic variants within
loci that encode alcohol metabolising enzymes. In both
examples, genetic variation results in altered exposure to
acetaldehyde, a metabolite of alcohol that causes unpleasant
symptoms, thought to be responsible for the different drinking
behaviour in individuals who possess the alleles.35Thus, a simple
interpretation of a mendelian randomisation analysis using a
genetic variant in an alcohol metabolising enzyme is that it is
akin to a long term randomised trial of more versus less alcohol
exposure.
Meaning of the study: possible explanations
and implications for clinicians and
policymakers and other researchers; how
your study could promote better decisions
These data show that individuals of European descent with a
genetic predisposition to consume less alcohol had a reduced
risk of coronary heart disease and ischaemic stroke, and lower
levels of several established and emerging risk factors for
cardiovascular disease. These findings suggest that reductions
of alcohol consumption, even for light to moderate drinkers,
may be beneficial for cardiovascular health. Our results therefore
challenge the concept of a cardioprotective effect associated
with light to moderate alcohol consumption reported in
observational studies and suggest that this effect may have been
due to residual confounding or selection bias.
Unanswered questions and future research
Although the association of the ADH1B variant with coronary
heart disease is compatible with being null in non-drinkers and
a more pronounced association is seen in drinkers, future access
to large scale population studies such as UKBiobank and China
Kadoorie Biobank Study will help to minimise potential
measurement error in alcohol exposure and provide sufficiently
large numbers of coronary heart disease events to enable
replication of our findings, in particular the analysis stratified
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by alcohol status, but will also allow a more detailed
examination of stroke subtypes.
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What is already known on this topic
Observational studies suggest that consuming alcohol in heavy amounts is deleterious for cardiovascular health, whereas light to
moderate consumption may be protective
However, findings for light to moderate drinkers could be due to unaccounted bias
What this study adds
Use of a genetic approach in an analysis of over 260 000 participants showed that carriers of a variant in the alcohol dehydrogenase
1B gene (ADH1B) associated with less alcohol consumption were found to have a reduced risk of coronary heart disease, and this was
maintained at all levels of alcohol consumption
Under the principles of mendelian randomisation, these findings suggest that reduction of alcohol consumption, even for light to moderate
drinkers, is beneficial for cardiovascular health
of researchers based at the National Centre for Social Research,
University College London and the Institute of Fiscal Studies. The data
were collected by the National Centre for Social Research.; EPIC
InterAct: We thank all EPIC participants and staff for their contribution
to the study. We thank staff from the Technical, Field Epidemiology and
Data Functional Group Teams of the MRC Epidemiology Unit in
Cambridge, UK, for carrying out sample preparation, DNA provision
and quality control, genotyping and data-handling work. The InterAct
study received funding from the European Union (Integrated Project
LSHM-CT-2006-037197 in the Framework Programme 6 of the European
Community); EPIC Netherlands: We thank Statistics Netherlands and
Netherlands Cancer Registry (NKR) for follow-up data on cancer,
cardiovascular disease, vital status and causes of death. Supported by
the European Commission: Public Health and Consumer Protection
Directorate 1993-2004; Research Directorate-General 2005; Dutch
Ministry of Public Health, Welfare and Sports; Netherlands Cancer
Registry; LK Research Funds; Dutch Prevention Funds; Dutch Zorg
Onderzoek Nederland; and World Cancer Research Fund (The
Netherlands) (to the European Prospective Investigation into Cancer
and Nutrition-Netherlands study). The EPIC-NL study was funded by
‘Europe against Cancer’ Programme of the European Commission
(SANCO), Dutch Ministry of Public Health, Welfare and Sports (VWS),
Netherlands Cancer Registry (NKR), LK Research Funds, Dutch
Prevention Funds, Dutch Cancer Society; ZonMW the Netherlands
Organisation for Health Research and Development, World Cancer
Research Fund (WCRF) (The Netherlands). Genotyping was funded
by IOP Genomics grant IGE05012 from Agentschap NL; EPIC Norfolk:
We thank all study participants and the general practitioners and the
EPIC-Norfolk study team for their helpful input. The EPIC-Norfolk study
is supported by programme grants from the Medical Research Council
and Cancer Research UK; EPIC Potsdam: The recruitment phase of
the EPIC-Potsdam Study was supported by the Federal Ministry of
Science, Germany (01 EA 9401), and the European Union (SOC
95201408 05F02). The follow-up was supported by the German Cancer
Aid (70-2488-Ha I) and the European Community (SOC 98200769
05F02). The present study was supported by the Federal Ministry of
Education and Research (0312750B). Mercodia provided the oxLDL
kits free of charge. JS and AFHP were supported by German Research
Federal Ministry (BMBF), JS was supported by a
Heisenberg-Professorship (SP716/1-1) and clinical research groups of
the German Research Foundation (DFG; KFO192/1 and 218/1). JS,
AFHP and MM were also supported by a graduate school of the DFG
(GK1208); EPIC Turin: The EPIC Turin study is funded by grants from
the Associazione Italiana per le Ricerche sul Cancro, Italy and grants
from the Compagnia di San Paolo, Turin, Italy; FHS: The Framingham
Heart Study began in 1948 with the recruitment of an original cohort of
5,209 men and women (mean age 44 years; 55 percent women). In
1971 a second generation of study participants was enrolled; this cohort
consisted of 5,124 children and spouses of children of the original cohort.
The mean age of the offspring cohort was 37 years; 52 percent were
women. A third generation cohort of 4,095 children of offspring cohort
participants (mean age 40 years; 53 percent women) was enrolled
beginning in 2002. At each clinic visit, a medical history was obtained
with a focus on cardiovascular content, and participants underwent a
physical examination including measurement of height and weight from
which BMI was calculated; HAPIEE: This study was supported by
Wellcome Trust ‘Determinants of Cardiovascular Diseases in Eastern
Europe: A multi-centre cohort study’ [grants 064947/Z/01/Z; and
081081/Z/06/Z]; the MacArthur Foundation ‘MacArthur Initiative on
Social Upheaval and Health’ [grant 712058]; the National Institute on
Ageing ‘Health disparities and aging in societies in transition (the
HAPIEE study)’ [grant 1R01 AG23522]; and a project from the Ministry
of Health, Czech Republic, for the development of the research
organization No. 00023001 (IKEM, Prague, Czech Republic). We would
like to thank researchers, interviewers and participants in Novosibirsk,
Krakow, Kaunas, Havířov/Karviná, Jihlava, Ústí nad Labem, Liberec,
Hradec Králové, and Kromĕříz.; HIMS: National Health and Medical
Research Council (NHMRC) project grants 279408, 379600, 403963,
513823 and 634492;HPFS/NHS: We would like to thank Hardeep Ranu
and Pati Soule from the DF/HCC Genotyping Core for genotyping and
data management. This study was supported by research grants
HL35464, CA55075, CA87969, AA11181, and HL34594 from the
National Institute of Health, Bethesda; M.D; IMPROVE: This study was
supported by the European Commission (Contract number: QLG1- CT-
2002- 00896), Ministero della Salute Ricerca Corrente, Italy, the Swedish
Heart-Lung Foundation, the Swedish Research Council (projects 8691
and 0593), the Foundation for Strategic Research, the StockholmCounty
Council (project 562183), the Foundation for Strategic Research, the
Academy of Finland (Grant #110413) and the British Heart Foundation
(RG2008/014). None of the aforementioned funding organizations or
sponsors has had a specific role in design or conduct of the study,
collection, management, analysis, or interpretation of the data, or
preparation, review, or approval of the manuscript; Inter99: The Inter99
study was supported by the Danish Medical Research Council, the
Danish Centre for Evaluation and Health Technology Assessment,
Copenhagen County, the Danish Heart Foundation, the Danish
Pharmaceutical Association, the Health Insurance Foundation, the
Augustinus Foundation, the Ib Henriksens foundation and the Beckett
Foundation. The present study was further supported by the Danish
Diabetes Association (grant No. 32, December 2005) and the Health
Insurance Foundation (grant No. 2010 B 131); ISGS/SWISS: ISGS
(Grant Number R01 42733) and SWISS (R01 NS39987) were funded
by grants from the National Institute of Neurological Disorders and
Stroke (US); Izhevsk: The Izhevsk Family Studies was funded by a UK
Wellcome Trust programme grant (078557); MDC: This work was
supported by the Swedish Medical Research Council; by the Swedish
Heart and Lung Foundation; by the Medical Faculty of Lund University,
Malmo University Hospital; by the Albert Pahlsson Research Foundation;
by the Crafoord foundation; by the Ernhold Lundstroms Research
Foundation, the Region Skane; by the Hulda and Conrad Mossfelt
Foundation; by the King Gustaf V and Queen Victoria Foundation; by
the Lennart Hanssons Memorial Fund; and by the Marianne andMarcus
Wallenberg Foundation. Genotyping was supported by the British Heart
Foundation (grant number CH/98001 to A.F.D., RG/07/005/23633 to
A.F.D., S.P.); MESA: The Multi-Ethnic Study of Atherosclerosis Study
(MESA) is a multicenter prospective cohort study initiated to study the
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g4164 doi: 10.1136/bmj.g4164 (Published 10 July 2014) Page 10 of 16
RESEARCH
development of subclinical cardiovascular disease. A total of 6814
women and men between the age of 45 and 84 year were recruited for
the first examination between 2000 and 2002. Participants were recruited
in six US cities (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los
Angeles County, CA; Northern Manhattan, NY; and St. Paul, MN). This
study was approved by the institutional review boards of each study
site, and written informed consent was obtained from all participants.
This cohort was genotyped as part of the National Heart Lung and Blood
Institute’s (NHLBI) Candidate Gene Association Resource (CARe)
(Musunuru, K., Lettre, G., Young, T., Farlow, D.N., Pirruccello, J.P.,
Ejebe, K.G., Keating, B.J., Yang, Q., Chen, M.H., Lapchyk, N. et al.
Candidate gene association resource (CARe): design, methods, and
proof of concept. Circ. Cardiovasc. Genet, 3, 267-275.);MRC 1958BC:
Dr Sue Ring and Dr Wendy McArdle (University of Bristol) and Mr Jon
Johnson (Centre for Longitudinal Studies, Institute of Education, London)
are thanked for help with data linkage. The study was supported by the
Academy of Finland (12926) and the Medical Research Council (MRC
G0601653 and SALVE/PrevMedsyn). The Medical Research Council
funded the 2002-2004 clinical follow-up of the 1958 birth cohort (grant
G0000934). This research used resources provided by the Type 1
Diabetes Genetics Consortium, a collaborative clinical study sponsored
by the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institute of Allergy and Infectious Diseases, National
Human Genome Research Institute, National Institute of Child Health
and Human Development, and Juvenile Diabetes Research Foundation
International (JDRF) and supported by U01 DK062418. This study
makes use of data generated by the Wellcome Trust Case-Control
Consortium. A full list of investigators who contributed to generation of
the data is available from theWellcome Trust Case-Control Consortium
website(www.wtccc.org.uk). Funding for the project was provided by
the Wellcome Trust under award 076113. Work at the Centre for
Paediatric Epidemiology and Biostatistics benefits from funding support
from the MRC in its capacity as the MRC Centre of Epidemiology for
Child Health. Research at the University College London Institute of
Child Health and Great Ormond Street Hospital for Children NHS Trust
benefits from R&D funding received from the NHS Executive; MRC
NSHD: Supported by Medical Research Council -- MC_UU_12019/1.
We are very grateful to the members of this birth cohort for their
continuing interest and participation in the study. We would like to
acknowledge the Swallow group, UCL, who performed the DNA
extractions; NHANES III: The findings and conclusions in this report
are those of the author(s) and do not necessarily represent the views
of the Centers for Disease Control and Prevention; NORDIL: This work
was supported by the British Heart Foundation (grant number CH/98001
to A.F.D., RG/07/005/23633 to A.F.D., S.P.) and a Special Project, for
genotyping of the Swedish extremes from the NORDIL andMDC cohorts;
and by Pharmacia. We thank Professor Thomas Hedner (Department
of Clinical Pharmacology, Sahlgrenska Academy, Gotheburg, Sweden)
and Professor Sverre Kjeldsen (Ullevaal University Hospital, University
of Oslo, Oslo, Norway), who are investigators of the NORDIL study.
Professor Kjeldsen is also an investigator of the ASCOT trial; NPHS II:
NPHS-II was supported by the British Medical Research Council, the
US National Institutes of Health (grant NHLBI 33014), and Du Pont
Pharma, Wilmington, Delaware; Portuguese stroke: Instituto Nacional
de Saude Doutor Ricardo Jorge; PREVEND: PREVEND genetics is
supported by the Dutch Kidney Foundation (Grant E033), The
Netherlands organisation for health research and development (ZonMw
grant 90.700.441), and the Dutch Inter University Cardiology Institute
Netherlands (ICIN); PROCARDIS: PROCARDIS was supported by the
EU FP7 Program (LSHM‐CT‐2007‐037273), AstraZeneca, the British
Heart Foundation, the Oxford BHF Centre of Research Excellence, the
Wellcome Trust core award (090532/Z/09/Z), the Swedish Research
Council, the Knut and Alice Wallenberg Foundation, the Swedish
Heart‐Lung Foundation, the Torsten and Ragnar Söderberg Foundation,
the Strategic Cardiovascular Program of Karolinska Institutet and
Stockholm County Council, the Foundation for Strategic Research and
the Stockholm County Council (560283); PROSPER: The PROSPER
study was supported by an investigator initiated grant obtained from
Bristol-Myers Squibb and by grants from the Interuniversity Cardiology
Institute of the Netherlands (ICIN) and the Durrer Center for
Cardiogenetic Research both Institutes of the Netherlands Royal
Academy of Arts and Sciences (KNAW), the Netherlands Heart
Foundation, the Center for Medical Systems Biology (CMSB), a center
of excellence approved by the Netherlands Genomics
Initiative/Netherlands Organisation for Scientific Research (NWO), the
Netherlands Consortium for Healthy Ageing (NCHA). The research
leading to these results has received funding from the European Union’s
Seventh Framework Programme (FP7/2007-2013) under grant
agreement n° HEALTH-F2-2009-223004 and by the Netherlands
Genomics Initiative (Netherlands Consortium for Healthy Aging grant
050-060-810); Rotterdam: The Rotterdam Study is supported by the
Erasmus Medical Center and Erasmus University Rotterdam; the
Netherlands Organization for Scientific Research (NWO); the
Netherlands Organization for Health Research and Development
(ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the
Netherlands Heart Foundation; the Ministry of Education, Culture and
Science; the Ministry of Health Welfare and Sports; the European
Commission; and the Municipality of Rotterdam. Support for genotyping
was provided by the Netherlands Organisation of Scientific Research
NWO Investments (nr. 175.010.2005.011, 911-03-012), the Research
Institute for Diseases in the Elderly (014-93-015; RIDE2), the
Netherlands Genomics Initiative (NGI)/Netherlands Consortium for
Healthy Aging (NCHA) project nr. 050-060-810; SMART: SMART
GENETICS was financially supported by BBMRI-NL, a Research
Infrastructure financed by the Dutch government (NWO 184.021.007);
TPT: TPT was funded by the Medical Research Council, the British
Heart Foundation, DuPont Pharma and Bayer Corporation; UCP: The
UCP study was funded by Veni grant Organization for Scientific
Research (NWO), Grant no. 2001.064 Netherlands Heart Foundation
(NHS), and TI Pharma Grant T6-101 Mondriaan. The department of
Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute
for Pharmaceutical Sciences, has received unrestricted research funding
from the Netherlands Organisation for Health Research and
Development (ZonMW), the Dutch Health Care Insurance Board (CVZ),
the Royal Dutch Pharmacists Association (KNMP), the private-public
funded Top Institute Pharma (www.tipharma.nl, includes co-funding
from universities, government, and industry), the EU Innovative
Medicines Initiative (IMI), EU 7th Framework Program (FP7), the Dutch
Medicines Evaluation Board, the Dutch Ministry of Health and industry
(including GlaxoSmithKline, Pfizer, and others); Whitehall II: The
Whitehall II study and Mika Kivimaki were supported by the Medical
Research Council; the British Heart Foundation; the Economic and
Social Research Council; the National Heart Lung and Blood Institute
(NHLBI: HL36310); and the National Institute on Aging (AG13196), US,
NIH;WHI: TheWHI program is funded by the National Heart, Lung, and
Blood Institute, National Institutes of Health, U.S. Department of Health
and Human Services through contracts HHSN268201100046C,
HHSN268201100001C,HHSN268201100002C,HHSN268201100003C,
HHSN268201100004C, and HHSN271201100004C. A listing of WHI
investigators can be found at https://cleo.whi.org/researchers/
Documents%20%20Write%20a%20Paper/WHI%20Investigator%
20Short%20List.pdf.
Statement of independence from funders: All researchers acted
independently of study funders. The study funders played no role in
study design and the collection, analysis, and interpretation of data and
the writing of the article and the decision to submit it for publication.
None of the funders influenced the data analysis or interpretation of
results. The comments made in this paper are those of the authors and
not necessarily those of any funders.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Prof
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g4164 doi: 10.1136/bmj.g4164 (Published 10 July 2014) Page 11 of 16
RESEARCH
Whittaker is 90% employed by GlaxoSmithKline and own shares in
GlaxoSmithKline. All other coauthors report no support from any
organisation for the submitted work; no financial relationships with any
organisations that might have an interest in the submitted work in the
previous three years; no other relationships or activities that could appear
to have influenced the submitted work.
Data sharing statement: No additional data available
Transparency declaration: The lead authors, MVH, CED, and JPC (the
manuscript’s guarantors) affirm that the manuscript is an honest,
accurate, and transparent account of the study being reported; that no
important aspects of the study have been omitted; and that any
discrepancies from the study as planned (and, if relevant, registered)
have been explained.
1 Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative
risk assessment of burden of disease and injury attributable to 67 risk factors and risk
factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of
Disease Study 2010. Lancet 2012;380:2224-60.
2 Rehm J, Baliunas D, Borges GL, Graham K, Irving H, Kehoe T, et al. The relation between
different dimensions of alcohol consumption and burden of disease: an overview. Addiction
2010;105:817-43.
3 Freiberg MS, Samet JH. Alcohol and coronary heart disease: the answer awaits a
randomized controlled trial. Circulation 2005;112:1379-81.
4 O’Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovascular health: the razor-sharp
double-edged sword. J Am Coll Cardiol 2007;50:1009-14.
5 Hansel B, Thomas F, Pannier B, Bean K, Kontush A, Chapman MJ, et al. Relationship
between alcohol intake, health and social status and cardiovascular risk factors in the
Urban Paris-Ile-de-France Cohort: is the cardioprotective action of alcohol a myth? Eur
J Clin Nutr 2010;64:561-8.
6 Corrao G, Rubbiati L, Bagnardi V, Zambon A, Poikolainen K. Alcohol and coronary heart
disease: a meta-analysis. Addiction 2000;95:1505-23.
7 Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol
consumption with selected cardiovascular disease outcomes: a systematic review and
meta-analysis. BMJ 2011;342:d671.
8 Boffetta P, Garfinkel L. Alcohol drinking and mortality among men enrolled in an American
Cancer Society prospective study. Epidemiology 1990;1:342-8.
9 Shaper AG, Wannamethee G, Walker M. Alcohol and mortality in British men: explaining
the U-shaped curve. Lancet 1988;2:1267-73.
10 Jackson R, Broad J, Connor J, Wells S. Alcohol and ischaemic heart disease: probably
no free lunch. Lancet 2005;366:1911-2.
11 Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption
on biological markers associated with risk of coronary heart disease: systematic review
and meta-analysis of interventional studies. BMJ 2011;342:d636.
12 Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association
between change in high density lipoprotein cholesterol and cardiovascular disease
morbidity and mortality: systematic review and meta-regression analysis. BMJ
2009;338:b92.
13 Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of
dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med
2012;367:2089-99.
14 Hingorani A, Humphries S. Nature’s randomised trials. Lancet 2005;366:1906-8.
15 Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute
to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
16 Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and
aldehyde dehydrogenase variants. Alcohol Res Health 2007;30:5-13.
17 Yokoyama A, Yokoyama T, Mizukami T, Matsui T, Kimura M, Matsushita S, et al. Blood
ethanol levels of nonabstinent Japanese alcoholic men in the morning after drinking and
their ADH1B and ALDH2 genotypes. Alcohol Alcoholism 2013 doi:10.1093/alcalc/agt136.
18 Macgregor S, Lind PA, Bucholz KK, Hansell NK, Madden PA, Richter MM, et al.
Associations of ADH and ALDH2 gene variation with self report alcohol reactions,
consumption and dependence: an integrated analysis. Hum Molecular Genetics
2009;18:580-93.
19 Bierut LJ, Goate AM, Breslau N, Johnson EO, Bertelsen S, Fox L, et al. ADH1B is
associated with alcohol dependence and alcohol consumption in populations of European
and African ancestry. Molecular Psychiatry 2012;17:445-50.
20 Lawlor DA, Nordestgaard BG, Benn M, Zuccolo L, Tybjaerg-Hansen A, Davey Smith G.
Exploring causal associations between alcohol and coronary heart disease risk factors:
findings from a Mendelian randomization study in the Copenhagen General Population
Study. Eur Heart J 2013;34:2519-28.
21 Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of
genome-wide association studies identifies common variants associated with blood
pressure variation in east Asians. Nature Genetics 2011;43:531-8.
22 Chen L, Davey Smith G, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a
systematic review implementing a Mendelian randomization approach. PLoS Med
2008;5:e52.
23 Drogan D, Sheldrick AJ, Schutze M, Knuppel S, Andersohn F, di Giuseppe R, et al. Alcohol
consumption, genetic variants in alcohol deydrogenases, and risk of cardiovascular
diseases: a prospective study and meta-analysis. PloS One 2012;7:e32176.
24 Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, et al. Concept,
design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale
genomic association studies. PloS One 2008;3:e3583.
25 InterAct Consortium, Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, et
al. Design and cohort description of the InterAct Project: an examination of the interaction
of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study.
Diabetologia 2011;54:2272-82.
26 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ 2003;327:557-60.
27 Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the
science and challenges for research. Addiction 2003;98(suppl 2):1-12.
28 Glymour MM, Tchetgen EJ, Robins JM. Credible Mendelian randomization studies:
approaches for evaluating the instrumental variable assumptions. AmJ Epidemiol
2012;175:332-9.
29 Hindorff LA, MacArthur J, Morales J, Junkins HA, Hall PN, Klemm AK, et al. A catalog of
published genome-wide association studies. National Human Genome Research Institute.
www.genome.gov/gwastudies (accessed Feb 2013).
30 Marmot MG, Davey Smith G, Stansfeld S, Patel C, North F, Head J, et al. Health
inequalities among British civil servants: the Whitehall II study. Lancet 1991;337:1387-93.
31 Voight BF, Kang HM, Ding J, Palmer CD, Sidore C, Chines PS, et al. The metabochip, a
custom genotyping array for genetic studies of metabolic, cardiovascular, and
anthropometric traits. PLoS Gen 2012;8:e1002793.
32 Room R. Smoking and drinking as complementary behaviours. Biomed Pharmacother
2004;58:111-5.
33 Tolstrup JS, Gronbaek M, Nordestgaard BG. Alcohol intake, myocardial infarction,
biochemical risk factors, and alcohol dehydrogenase genotypes. Circ Cardiovasc Genet
2009;2:507-14.
34 Husemoen LL, Jorgensen T, Borch-Johnsen K, Hansen T, Pedersen O, Linneberg A. The
association of alcohol and alcohol metabolizing gene variants with diabetes and coronary
heart disease risk factors in a white population. PLoS One 2010;5:e11735.
35 Quertemont E, Didone V. Role of acetaldehyde in mediating the pharmacological and
behavioral effects of alcohol. Alcohol Res Health 2006;29:258-65.
Accepted: 21 May 2014
Cite this as: BMJ 2014;349:g4164
Related links
bmj.com/archive
• Clinical Review: Translating genomics into improved
healthcare (BMJ 2010;341:c5945)
• Clinical Review: A practical guide to interpretation and
clinical application of personal genomic screening (BMJ
2009;339:b4253)
• Editorials: Direct to consumer genetic testing (BMJ 2011;
342:d2317)
This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute,
remix, adapt, build upon this work non-commercially, and license their derivative works
on different terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g4164 doi: 10.1136/bmj.g4164 (Published 10 July 2014) Page 12 of 16
RESEARCH
Tables
Table 1| Pooled estimates of association between genetic variant ADH1B rs1229984 (A-allele carriers v non-carriers) and measures of
alcohol consumption. (Summary effect estimates are derived from fixed effects meta-analysis)
I2 value (%)P valueEffect estimate (95% CI)No of studies, cases/individualsAlcohol consumption measure
% differenceLog transformed data*
645.5×10−76−17.22 (−18.86 to −15.55)46, NA/218 969Intake volume (units/week†)
360.028−1.84 (−3.40 to −0.26)15, NA/97 755γ-glutamyltransferase level (U/L)
Odds ratioCategorical data
609.8×10−670.70 (0.68 to 0.73)45, 69 229/222 332Top tertile of alcohol intake
471.4×10−120.78 (0.73 to 0.84)21, 22 198/131 290Binge drinker‡
732.6×10−191.27 (1.21 to 1.34)32, 24 482/189 854Alcohol abstainer‡
NA = not applicable.
*Non-normally distributed variables were natural log transformed and mean differences on the log scale were converted to percentage differences.
†Alcohol units in British units; 1 UK unit = 0.57 US units or 10 mL (7.9 g) ethanol.
‡For definitions of binge drinker and alcohol abstainer, see table S2 in appendix.
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Table 2| Pooled estimates of association between genetic variant ADH1B rs1229984 (A-allele carriers v non-carriers) and cardiovascular
biomarkers in all participants. (Summary effect estimates are derived from fixed effects meta-analysis and are reported asmean differences
unless stated otherwise)
I2 value (%)P valueEffect estimate (95% CI)No of studies, individualsBiomarker
264.1×10−8−0.88 (−1.19 to −0.56)48, 227 559Systolic blood pressure (mm Hg)
Anthropometric measures:
523.4×10−6−0.17 (−0.24 to −0.10)51, 232 570Body mass index (weight (kg)/(height (m)2))
416.2×10−3−0.34 (−0.58 to −0.10)42, 140 923Waist circumference (cm)
Inflammation:
332.90×10−4−5.15 (−7.82 to −2.40)17, 30 950Log transformed interleukin 6 (% difference)*
14.60×10−3−3.40 (−5.68 to −1.05)42, 124 498Log transformed C reactive protein (% difference)*
Lipids:
255.10×10−3−0.03 (−0.05 to −0.01)46, 202 794Non-HDL cholesterol (mmol/L)
368.90×10−41.61 (0.66 to 2.57)46, 205 824Log transformed triglycerides (% difference)*
540.259−0.004 (−0.012 to 0.003)46, 203 440HDL cholesterol (mmol/L)
*Non-normally distributed variables were natural log transformed and mean differences on the log scale were converted to percentage differences.
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Figures
Fig 1 Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers v non-carriers) and
cardiovascular disease biomarkers showing association on crude analysis, stratified by alcohol intake
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Fig 2 Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers v non-carriers) and
coronary heart disease overall, and stratified by alcohol intake
Fig 3 Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers v non-carriers) and
stroke (combined subtypes) and type 2 diabetes overall, and stratified by alcohol intake
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